<< Back to News

System Formulary Update
Tremelimumab-actl (Imjudo)

Situation

Tremelimumab-actl (Imjudo) 20 mg/mL (25 mg SDV and 300 mg SDV) for injection was approved for addition to the health system formulary at the March 2023 System Pharmacy and Therapeutics Committee meeting. 

Background

The following medication was reviewed: Tremelimumab-actl (Imjudo) 20 mg/mL (25 mg SDV and 300 mg SDV) for injection

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Tremelimumab-actl (Imjudo) 20 mg/mL (25 mg SDV and 300 mg SDV) for injection

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, April 18, 2023.